SPRINTER: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Determine the Efficacy and Safety of Inhaled Interferon Beta-1a (SNG001) for the Treatment of Patients Hospitalised Due to COVID-19 (NCT04732949)

Source: International Congress 2022 – ALERT 3: COVID and interstitial lung diseases??

Session: ALERT 3: COVID and interstitial lung diseases??
Session type: Clinical trials session
Number: 2884

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Monk (Southampton, United Kingdom), J. Brookes (Southampton, United Kingdom), V. Tear (Southampton, United Kingdom), T. Batten (Twickenham, United Kingdom), M. Mankowski (Wokingham, United Kingdom), M. Kraft (Tucson, United States), C. Brightling (Leicester, United Kingdom), F. Gabbay (Wokingham, United Kingdom), S. Holgate (Southampton, United Kingdom), R. Djukanovic (Southampton, United Kingdom), T. Wilkinson (Southampton, United Kingdom). SPRINTER: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Determine the Efficacy and Safety of Inhaled Interferon Beta-1a (SNG001) for the Treatment of Patients Hospitalised Due to COVID-19 (NCT04732949). 2884

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

• Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
• Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
• Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living